At ATTD 2026, the discussion around Continuous Glucose Monitoring (CGM) is shifting. While trend arrows offer valuable insight, the next leap in diabetes management lies in empowering patients with reliable, actionable, and predictive information.
Join us for a pivotal Roche Symposium where leading diabetes experts will explore how advanced glucose prediction is fundamentally transforming clinical practice.
Prof. Kirsten Nørgaard (Denmark)
Prof. Bogdan Timar (Romania)
Dr Guido Freckmann (Germany)
Lucía Feito Allona (Spain)
Kirsten Nørgaard, MD, DMSc is a Professor in Clinical Diabetes Technology at Copenhagen University, Denmark...
Francisco Javier Ampudia-Blasco, MD, PhD, is Full Professor of Medicine at the University of Valencia and Section Chief...
Prof. Timar, MD, PhD is the dean of the Faculty of Medicine at Victor Babes University of Medicine and Pharmacy and...
Dr Freckmann, MD is a Medical Director and General Manager of the Institut für Diabetes-Technologie...
Lucía is a diabetes educator and person living with type 1 diabetes. As a lawyer in global health and educator...
The new continuous glucose monitoring solution offers easy access to real-time CGM data and glucose predictions that may help reduce the risk of highs and lows and support improved diabetes management¹.
The Accu-Chek SmartGuide CGM solution is getting an upgrade. It’s time to move to the mySugr app – one powerful app with more than 7 million* registered accounts worldwide.
*Total cumulative registrations since launch
Everything you and your patients rely on stays the same: real-time CGM data, patterns, alarms, and predictions stay right where one expects them.
When connected, the mySugr app automatically shares⁴ your patients’ diabetes data from the Accu-Chek SmartGuide CGM solution with Accu-Chek Care.
References:
1. Simulation study, study data not published yet, data on file, Roche Diabetes Care GmbH, 2025.
2. Moving from the Accu-Chek SmartGuide app and Accu-Chek SmartGuide Predict app to one app (the mySugr app) brings you more tools for tracking meals, activity, and health.
3. Access to Accu-Chek Care platform is required.
4. User consent is required.
The product shown is a medical device intended for use by patients with diabetes aged 18+ years; please use only as directed and consult a healthcare professional if needed.
The people shown in photographs are models for illustrative purposes only and are not real-life patients. The screens you see may differ from the screens in the app. Smartphone required, not included in the solution.
This website and its contents are intended for healthcare professionals in countries where Accu-Chek SmartGuide has received regulatory clearance (including the European Union). This information is not intended for users in jurisdictions where such clearances have not been granted, including the United States.
Accu-Chek SmartGuide is a CE-marked medical device. Availability may vary by country.
ACCU-CHEK, ACCU-CHEK SMARTGUIDE, MYSUGR are trademarks of Roche. All other product names and trademarks are property of their respective owners.
© 2026 Roche Diagnostics Ltd. All rights reserved
